High out-of-pocket costs can make lifesaving medications out of reach for millions of Americans with cardiovascular disease

November 25, 2019

Research Highlights:

DALLAS, Nov. 25, 2019 -- One in 8 adults with common heart diseases and stroke skip taking medications, delay filling prescriptions or take lower doses than prescribed because of concerns about cost, according to new research published today in the American Heart Association's journal Circulation.

"The out-of-pocket cost of medications is a huge issue for millions of high-risk patients with cardiovascular diseases such as heart attacks, stroke, angina and other conditions. When faced with the expenses of taking lifesaving medications as prescribed or not taking them because they are too costly, many choose not to take them," said Khurram Nasir, M.D., M.P.H., M.Sc., senior author of the study, chief of the division of cardiovascular prevention and wellness and co-director of the Center for Outcomes Research at Houston Methodist DeBakey Heart & Vascular Center in Texas.

Not taking pills at the dose or the interval prescribed, called medication non-compliance, is a known problem for people with cardiovascular diseases. It often means they need more expensive care later because they become sicker and are more likely to need care in an emergency room, be hospitalized or have more frequent doctor's appointments.

"While non-compliance has several causes, in recent years the rising share of health care costs paid directly by patients has become a concern. We wanted to understand the scope of medication non-compliance due to costs," said Nasir.

The investigators analyzed survey responses from 14,279 adults (average age 65, 44 % female) who took part in the National Health Interview Survey between 2013 and 2017. All had previously been diagnosed with coronary heart disease, heart-related chest pain, a heart attack or a stroke.

The researchers found that, during the previous year:

1 in 8 people with these common heart diseases (corresponding to nearly 2.2 million people nationwide) had not taken their medication as prescribed because of cost concerns;

Cost-related, medication non-compliance was 3 times more common in people under 65 years of age, with nearly 1 in 5 reporting cost-related non-compliance;

Among those under 65, larger proportions of women (1 in 4), patients from low-income families (1 in 3) and patients without health insurance (more than half) reported not taking their medications as prescribed in order to save money;

Race and level of education did not have a significant effect on the proportion of patients with cost-related non-compliance; and

People who did not take medications as prescribed due to cost concerns were 11 times more likely to request low-cost medication and 9 times more likely to use alternative, non-prescription therapies, compared to people who reported that financial concerns did not impact their decision.

"Patients should not be afraid to speak with their health care provider if they are not able to afford a prescribed medication since there are many lower-cost generic drugs which might also be effective for their condition," said Nasir.

"As health care providers, we should also consider advocating for changes in national health care policy, such as capping out-of-pocket expenses for low-income families. We also need to recognize that out-of-pocket medical costs may have a cumulative effect on a patient's family who may also have difficulty paying for housing, transportation and food. Health care providers can play an active role in working with our local health system and community financial assistance support programs to provide financial assistance and resources to those who need it the most," Nasir added.

The study did not examine the specific medications patients were prescribed and which were more likely to result in cost-related non-compliance.

As an evidence-based patient advocacy organization dedicated to improving the cardiovascular health of all Americans, the American Heart Association has a unique role in advocating for treatments, including medicines that are available, affordable and accessible to patients. Our 2017 Presidential Advisory on the accessibility and affordability of prescription drugs and biologics lays out the principles that guide our engagement in pursuit of this goal.
-end-
Co-authors are Rohan Khera, M.D.; Javier Valero-Elizondo, M.D., M.P.H.; Sandeep R. Das, M.D., M.P.H.; Salim S. Virani, M.D., Ph.D.; Bita A. Kash, Ph.D., M.B.A.; James A. de Lemos, M.D.; and Harlan M. Krumholz, M.D., S.M. Author disclosures are in the manuscript.

The National Center for Advancing Translational Sciences supported the study.

Additional Resources:

Available multimedia is on right column of release link - https://newsroom.heart.org/news/high-out-of-pocket-costs-can-make-lifesaving-medications-out-of-reach-for-millions-of-americans-with-cardiovascular-disease?preview=824c568851545174f7eccffc503e6013

After Nov. 25, 2019, view the manuscript online and a commentary from The American Heart Association's Center for Health Statistics and Evaluation online.

Medicine Assistance Programs
Taking Control of Your Medicines
Why Not Comply Part I
Why Not Comply Part II
American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics: A Presidential Advisory from the American Heart Association

Follow AHA/ASA news on Twitter @HeartNews

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

American Heart Association

Related Cardiovascular Diseases Articles from Brightsurf:

Graz researchers identify biomarker for cardiovascular diseases
The role of the enzyme dipeptidyl peptidase 3 in the blood pressure-regulating renin-angiotensin system was investigated in the inter-university cooperation project BioTechMed-Graz.

Glomerular diseases linked to higher risk of cardiovascular conditions
Adults with glomerular diseases have a 2.5-times higher risk of developing cardiovascular disease than individuals in the general population.

New insight into neovessel formation shows promise in future treatment of cardiovascular diseases
A new study by researchers at the University of Eastern Finland provides novel insight into the previously unknown effects of factors regulating blood vessel formation.

Research reveals cilia's role in cardiovascular functions and genetic diseases
Research from Chapman University discover ciliary extracellular-like vesicles (cELVs). Released by fluid-shear, cELVs act as nano-compartments within a cilium.

Stretching your legs may help prevent diseases such as heart diseases and diabetes
New research published today in The Journal of Physiology shows that 12 weeks of easy-to-administer passive stretching helps improve blood flow by making it easier for your arteries to dilate and decreasing their stiffness.

Framework on how to safely resume essential cardiovascular diagnostic and treatment care during the COVID-19 pandemic, from the AHA and 14 North American cardiovascular societies
The American Heart Association, together with 14 cardiovascular societies in North America, today issued joint guidance, 'Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership,' to outline a systematic, phased approach to safely reintroducing cardiovascular procedures for diagnosis and treatment during the COVID-19 pandemic.

Cardiovascular impairment in COVID-19
Anti-inflammatory therapies should be used to treat COVID-19 patients that are at risk of, or have developed, cardiovascular problems, recommend leading cardiologists from Beijing, China, who have detailed the different ways that COVID-19 could trigger serious inflammatory-related cardiovascular issues in patients.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Serum irisin: Pathogenesis and clinical research in cardiovascular diseases
In a new publication from Cardiovascular Innovations and Applications; Lutfu Askin, Kader Eliz Uzel, Okan Tanriverdi and Serdar Turkmen from the Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey consider serum irisin pathogenesis and clinical research in cardiovascular diseases.

Improving cardiovascular health of the most vulnerable
A two-year pilot project led by Rick Stouffer, MD, shows how the cardiovascular health of the most vulnerable patients can be improved with free medications.

Read More: Cardiovascular Diseases News and Cardiovascular Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.